CytRx Wins Favorable Novel Combination of Aldoxorubicin-Doxorubicin

CytRx Corporation CYTR, a biopharmaceutical research and development company specializing in oncology, announced that preliminary results from a Phase 1b clinical trial determined that aldoxorubicin, the Company's improved version of the widely used chemotherapeutic agent doxorubicin, administered at 90% of its single agent dose can be safely delivered in combination with doxorubicin administered at 50% of its single agent dose to patients with advanced solid tumors. The data from this clinical trial will be discussed today in a poster presentation at the American Society of Clinical Oncology (ASCO) conference in Chicago. The Phase 1b data was included in an abstract, “Phase 1b Trial of Combining Aldoxorubicin Plus Doxorubicin,” authored by Kamalesh Kumar Sankhala, M.D.; Sant P. Chawla, M.D.; Victoria S. Chua; Doris Quon, M.D.; Allison Bonk; Vivek Narashimhan; Monish Sodhi; and Nina Krishna, from the Sarcoma Oncology Center in Santa Monica, Calif., and Hillary Dinh, Ph.D., Scott Wieland, Ph.D., CytRx's Senior Vice President of Drug Development, and Daniel Levitt, M.D., Ph.D., CytRx's Executive Vice President and Chief Medical Officer. Dr. Sankhala, of the Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, presented the data at the ASCO conference. Studies in animal models of human pancreatic and ovarian cancers conducted at the Tumor Biology Institute in Freiburg, Germany demonstrated that aldoxorubicin plus doxorubicin administered at 50% of their respective maximum tolerated doses provided complete and prolonged tumor remission with minimal weight loss compared with each drug administered at its individual maximum tolerated dose. Results of this research were published in the peer-reviewed International Journal of Pharmaceutics. Clinical and preclinical trials indicate that aldoxorubicin, which combines doxorubicin with a proprietary protein-binding linker platform technology, concentrates doxorubicin at the site of the tumor, thereby reducing the toxic side effects associated with systemic delivery. CytRx holds the exclusive worldwide rights to aldoxorubicin, as well as option rights to the platform technology that serves as the linker with doxorubicin.